Results 181 to 190 of about 8,509,826 (346)

The Comparative Dose-Response Effects of Melatonin and Midazolam for Premedication of Adult Patients: A Double-Blinded, Placebo-Controlled Study

, 2000
Mohamed Naguib, Abdulhamid H. Samarkandi
openalex   +2 more sources

Is placebo analgesia for heat pain a sensory effect? An exploratory study on minimizing the influence of response bias

Neurobiology of Pain, 2019
We explored the ongoing question of whether placebo analgesia alters afferent nociceptive processing in a novel paradigm designed to minimize the role of response bias in placebo measurement.
Laura K. Case, Claire M. Laubacher, Emily A. Richards, Matthew Grossman, Lauren Y. Atlas, Scott Parker, M. Catherine Bushnell   +6 more
doaj  

Cortical morphology predicts placebo response in multiple sclerosis. [PDF]

Sci Rep, 2022
Cherkasova MV, Fu JF, Jarrett M, Johnson P, Abel S, Tam R, Rauscher A, Sossi V, Kolind S, Li DKB, Sadovnick AD, Machan L, Girard JM, Emond F, Vosoughi R, Traboulsee A, Stoessl AJ.   +16 more
europepmc   +1 more source

The usefulness of DST in predicting response to antidepressants: A placebo-controlled study

, 1986
Anastasios Georgotas, Peter E. Stokes, Robert E. McCue, Arthur Dubow, Joan Welkowitz, Eitan Friedman, C Fanelli, I. Chang, Thomas B. Cooper   +8 more
openalex   +1 more source

“Stepping-up” from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate [PDF]

, 2001
Marc C. Hochberg, J. Kathleen Tracy, Rody Huaman Flores   +2 more
openalex   +1 more source

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, EarlyView.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Placebo response in antidepressant trials [PDF]

, 2001
Daniel L. Zimbroff
openalex   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

The Placebo Response and the “Natural History” of Inflammatory Bowel Disease [PDF]

, 2001
Henry D. Janowitz, Carol Bodian
openalex   +1 more source

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis

Neuropsychopharmacology, 2019
S. Leucht, A. Chaimani, D. Mavridis, C. Leucht, M. Huhn, B. Helfer, M. Samara, A. Cipriani, J. Geddes, John M. Davis   +9 more
semanticscholar   +1 more source